.png){kind=icon}
.png){kind=icon}
Return
Small but powerful
.png){kind=icon}
PRE
AI
DOI：10.1038/s41570-025-00772-w.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Fifty years ago, researchers from Beecham Pharmaceuticals reported on the structure of clavulanic acid. Itself only a weak antibiotic, clavulanic acid inhibits serine β-lactamases and thus this work pioneered combination therapy to protect antibiotics against the development of resistance.
Keywords:
clavulanic acid
β-lactamases
antibiotic resistance
combination therapy
serine β-lactamases
Journal
IF:
51.7
Papers:
1.0K
Citations:
1.6W